



**Figure 1**




**Figure 2**




**Figure 3**

Immunolabeling for  $\alpha$ -SMA



control



cCAF-treated






Figure 4






control




cCAF




N-peptide



**Figure 5**




**Figure 6**



**Figure 7**



control (day 0)





cCAF (day 0)




control (day 3)






cCAF (day 3)



**Figure 8**



**Figure 9**



**Figure 10**

# *Summary of cCAF/Peptide effects on cCXCR1*




Figure 11